title: Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma.
abstract: PTT-119, a new synthetic alkylating compound, has shown a marked "in vitro" inhibitory effect on chronic myeloid leukemia (CML) granulo-monocytic precursors (CFU-GM) at doses greater than 5 micrograms/ml. Based on previous experiences of synergistic associations between alkylating drugs and biological modifiers, we tested the effects of low doses of PTT-119 (from 0.1 to 1 microgram/ml) in concert with alpha, gamma, or alpha + gamma interferons and compared to IFNs alone, in order to investigate an alternative choice for treatment of CML patients in chronic phase. Our results showed a significantly higher CFU-GM cloning inhibition after addition of 100 or 1,000 U/ml of alpha IFN to 0.1 microgram/ml PTT-119 (from 39.6% +/- 26.6 SD to 80.7% +/- 10 SD and 91.5% +/- 8 SD, respectively), while gamma IFN resulted in only a slight increase in colony growth inhibition when compared to the drug used alone. The association of alpha plus gamma IFN coupled with PTT-119 treatment did not significantly improve the results observed after exposure of leukemic progenitors to PTT-119 and alpha IFN alone. We conclude that a combined treatment with PTT-119 and IFN is probably worth testing both for purging methods before autologous bone marrow transplantation and for in vivo administration in chronic myeloid leukemia.
authors.affiliation: Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: R M
authors.initials: RM
authors.lastname: Lemoli
authors.forename: P
authors.initials: P
authors.lastname: Tosi
authors.forename: F
authors.initials: F
authors.lastname: Verlicchi
authors.forename: B
authors.initials: B
authors.lastname: Gamberi
authors.forename: A R
authors.initials: AR
authors.lastname: Cenacchi
authors.forename: R
authors.initials: R
authors.lastname: Colombini
authors.forename: M
authors.initials: M
authors.lastname: Fogli
authors.forename: D
authors.initials: D
authors.lastname: Russo
authors.forename: E
authors.initials: E
authors.lastname: Zuffa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood*; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology*; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D009588:Nitrogen Mustard Compounds; D011994:Recombinant Proteins; D007371:Interferon-gamma; C038259:ambamustine